Nisa Investment Advisors
CUE icon

Nisa Investment Advisors’s Cue Biopharma CUE Stock Holding History

Nisa Investment Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$53 – 2804
2023
Q4 		$53 Buy
+1
New +$71 ﹤0.01% 2628
2022
Q1 		– Sell
-101
Closed -$22K – 2362
2021
Q4 		$22K Sell
101
-64
-39% -$24.8K ﹤0.01% 1905
2021
Q3 		$72 Sell
165
-17
-9% -$5.93K ﹤0.01% 1832
2021
Q2 		$63 Buy
182
+165
+971% +$64K ﹤0.01% 1874
2021
Q1 		$6 Sell
17
-16
-48% -$6.58K ﹤0.01% 2249
2020
Q4 		$13K Buy
+33
New +$13.2K ﹤0.01% 2180

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nisa Investment Advisors's CUE Position: Q1 2024 in Review

Nisa Investment Advisors sold out of Cue Biopharma (CUE) in Q1 2024, closing a stake of 1 share — an estimated $53 sold.

Nisa Investment Advisors first reported a position in CUE in Q4 2020 and held it in 6 quarters. The position peaked at $22K in Q4 2021. 74 funds tracked by Wall St. Rank hold CUE as of Q1 2024.

  • Nisa Investment Advisors reported no remaining Cue Biopharma position as of Q1 2024 after selling out during the quarter.
  • Nisa Investment Advisors sold 1 Cue Biopharma share in Q1 2024, an estimated $53.
  • Nisa Investment Advisors first reported a position in Cue Biopharma in Q4 2020 and held it in 6 quarters.
  • Nisa Investment Advisors's Cue Biopharma position peaked at $22K in Q4 2021.
  • 74 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2024.

Based on Nisa Investment Advisors's 13F filing for Q1 2024, filed 2 May 2024.